Business Context and Reporting Period
This Form 8-K was filed by Ra Medical Systems, Inc. on May 16, 2023. The report addresses the quarter ended March 31, 2023. Following a merger with Catheter Precision, Inc. on January 9, 2023, the registrant's business focus has shifted to Catheter's products. Consequently, the financial results for the current quarter relate primarily to Catheter's products, whereas the prior year quarter related to legacy Ra Medical products which are no longer pursued.
Key Financial Metrics
- Projected Revenue (Q1 2023): Approximately $85,000.
- Reported Revenue (Q1 2022): $9,000.
- Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The filing explicitly states that financial results for the quarter ended March 31, 2023, are not comparable to the quarter ended March 31, 2022, due to the change in business focus following the merger. While revenue is projected to increase from $9,000 to approximately $85,000, this increase reflects the shift to Catheter Precision's product line rather than organic growth of the legacy business.
Guidance, Outlook, and Risks
The revenue projection of approximately $85,000 is preliminary and subject to adjustment when final numbers are reported. Potential adjustments may result from factors including the input of the Company's auditors during their review process. The registrant filed a Form 12b-25 to project these results.
Investor Verification Checklist
- Verify the final audited revenue figures for the quarter ended March 31, 2023, once the full financial report is released.
- Confirm the specific product mix and revenue contribution from Catheter Precision, Inc. post-merger.
- Review the upcoming full financial statements for details on profit, cash flow, and liquidity, which are not detailed in this 8-K.
- Monitor for any adjustments to the preliminary $85,000 revenue projection.